{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:38Z","timestamp":1790474138083,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA160250"],"award-info":[{"award-number":["CA160250"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.semcancer.2019.09.014","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T11:34:49Z","timestamp":1568979289000},"page":"11-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies"],"prefix":"10.1016","volume":"61","author":[{"given":"Trista K.","family":"Hinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Heasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semcancer.2019.09.014_bib0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.trecan.2016.07.004","article-title":"Malignant mesothelioma: time to translate?","volume":"2","author":"Napolitano","year":"2016","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S2213-2600(19)30004-9","article-title":"Pleural mesothelioma: tackling a deadly cancer","volume":"7","author":"M. The Lancet Respiratory","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/jdb7020007","article-title":"Mesothelium and malignant mesothelioma","volume":"7","author":"Hiriart","year":"2019","journal-title":"J. Dev. Biol."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","article-title":"The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?","volume":"107","author":"Bronte","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"14","key":"10.1016\/j.semcancer.2019.09.014_bib0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0035","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"10026","key":"10.1016\/j.semcancer.2019.09.014_bib0045","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"I. French Cooperative Thoracic, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0050","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(18)30868-4","article-title":"Checkpoint inhibitors in mesothelioma: hope for the future?","volume":"20","author":"Bibby","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"I. French Cooperative Thoracic, Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.014_bib0070","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0075","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-14-2748","article-title":"Lung cancer in the era of precision medicine","volume":"21","author":"Politi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0080","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0085","doi-asserted-by":"crossref","DOI":"10.3390\/ht7030020","article-title":"Genomics and epigenetics of malignant mesothelioma","volume":"7","author":"Sage","year":"2018","journal-title":"High Throughput"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/PPO.0000000000000242","article-title":"Novel targeted therapies for metastatic melanoma","volume":"23","author":"Iams","year":"2017","journal-title":"Cancer J."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","article-title":"Current chemotherapy strategies in malignant pleural mesothelioma","volume":"7","author":"de Gooijer","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0105","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"issue":"Database issue","key":"10.1016\/j.semcancer.2019.09.014_bib0110","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0115","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in Cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"issue":"7391","key":"10.1016\/j.semcancer.2019.09.014_bib0120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0130","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2018.03.009","article-title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","volume":"119","author":"Sneddon","year":"2018","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.semcancer.2019.09.014_bib0140","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1158\/0008-5472.CAN-05-2312","article-title":"A mouse model recapitulating molecular features of human mesothelioma","volume":"65","author":"Altomare","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.semcancer.2019.09.014_bib0150","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","article-title":"Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models","volume":"79","author":"Kukuyan","year":"2019","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.014_bib0155","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/j.jtho.2017.04.028","article-title":"Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with afatinib","volume":"12","author":"Agatsuma","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational profiling of malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0165","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jclinpath-2011-200631","article-title":"Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma","volume":"65","author":"Enomoto","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/PDM.0b013e3182a3645e","article-title":"Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany","volume":"23","author":"Schildgen","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.014_bib0175","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"7295","key":"10.1016\/j.semcancer.2019.09.014_bib0180","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2012.288","article-title":"The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics","volume":"27","author":"Abdel-Wahab","year":"2013","journal-title":"Leukemia"},{"issue":"6437","key":"10.1016\/j.semcancer.2019.09.014_bib0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.aav4902","article-title":"Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1","volume":"364","author":"He","year":"2019","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0195","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12885-019-5314-0","article-title":"Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro","volume":"19","author":"Borchert","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0210","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","article-title":"YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-Deficient tumor cells","volume":"49","author":"White","year":"2019","journal-title":"Dev. Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040090","article-title":"Targeting the hippo pathway is a new potential therapeutic modality for malignant mesothelioma","volume":"10","author":"Sekido","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","author":"Woodard","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0225","first-page":"75","article-title":"Hippo\/YAP pathway for targeted therapy","volume":"3","author":"Felley-Bosco","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0230","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41388-018-0417-7","article-title":"TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation","volume":"38","author":"Matsushita","year":"2019","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0235","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0240","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/carcin\/bgn200","article-title":"YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation","volume":"29","author":"Yokoyama","year":"2008","journal-title":"Carcinogenesis"},{"issue":"237","key":"10.1016\/j.semcancer.2019.09.014_bib0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0250","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0255","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0260","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0265","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000950","article-title":"Posttranslational modification of p53: cooperative integrators of function","volume":"1","author":"Meek","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0270","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0280","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cc.27546","article-title":"Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma","volume":"13","author":"Di Marzo","year":"2014","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.014_bib0285","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1593\/neo.06148","article-title":"p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma","volume":"8","author":"Hopkins-Donaldson","year":"2006","journal-title":"Neoplasia"},{"key":"10.1016\/j.semcancer.2019.09.014_bib0290","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1155\/2018\/1986982","article-title":"Inhibition of MDM2 via Nutlin-3A: a potential therapeutic approach for pleural mesotheliomas with MDM2-Induced inactivation of wild-type P53","volume":"2018","author":"Walter","year":"2018","journal-title":"J. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0295","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0300","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drudis.2016.07.010","article-title":"Exploiting receptor tyrosine kinase co-activation for cancer therapy","volume":"22","author":"Tan","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0305","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0310","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"issue":"5\u20136","key":"10.1016\/j.semcancer.2019.09.014_bib0315","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1159\/000176386","article-title":"Mesothelioma cell proliferation through autocrine activation of PDGF-betabeta receptor","volume":"29","author":"Honda","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"issue":"15","key":"10.1016\/j.semcancer.2019.09.014_bib0320","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.ejca.2010.06.130","article-title":"Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma","volume":"46","author":"Perrone","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"1-2","key":"10.1016\/j.semcancer.2019.09.014_bib0325","doi-asserted-by":"crossref","first-page":"438","DOI":"10.18632\/genesandcancer.129","article-title":"Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines","volume":"8","author":"Melaiu","year":"2017","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.014_bib0330","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2009.02.022","article-title":"Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines","volume":"45","author":"Nutt","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"14","key":"10.1016\/j.semcancer.2019.09.014_bib0335","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/onc.2010.555","article-title":"AXL regulates mesothelioma proliferation and invasiveness","volume":"30","author":"Ou","year":"2011","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0340","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/bjc.2013.9","article-title":"The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma","volume":"108","author":"Pinato","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0345","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6605184","article-title":"Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma","volume":"101","author":"Jacobson","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0350","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.athoracsur.2006.04.013","article-title":"Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma","volume":"82","author":"Whitson","year":"2006","journal-title":"Ann. Thorac. Surg."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0355","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Marek","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0360","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13287-017-0573-7","article-title":"The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells","volume":"8","author":"Pattarozzi","year":"2017","journal-title":"Stem Cell Res. Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.014_bib0365","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0370","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1593\/neo.101156","article-title":"Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma","volume":"13","author":"Ou","year":"2011","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0375","first-page":"318","article-title":"Advances and challenges in targeting FGFR signalling in cancer, Nature reviews","volume":"17","author":"Babina","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2019.09.014_bib0380","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"178","key":"10.1016\/j.semcancer.2019.09.014_bib0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005414","article-title":"Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer","volume":"5","author":"Harding","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"26","key":"10.1016\/j.semcancer.2019.09.014_bib0395","doi-asserted-by":"crossref","first-page":"39861","DOI":"10.18632\/oncotarget.9515","article-title":"Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230","volume":"7","author":"Blackwell","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.014_bib0400","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/1756-0500-7-549","article-title":"Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study","volume":"7","author":"Plones","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.semcancer.2019.09.014_bib0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario clinical oncology group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0410","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0415","article-title":"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma","author":"van Brummelen","year":"2019","journal-title":"Invest. New Drugs"},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0420","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0425","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.cllc.2018.09.001","article-title":"Preselection of lung Cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib","volume":"20","author":"Ng","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.014_bib0430","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0435","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fgene.2018.00232","article-title":"Pre-clinical models for malignant mesothelioma research: from chemical-induced to patient-derived Cancer xenografts","volume":"9","author":"Nabavi","year":"2018","journal-title":"Front. Genet."},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.014_bib0440","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","article-title":"Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease","volume":"23","author":"Chernova","year":"2016","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0445","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0450","first-page":"15","article-title":"Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma","volume":"376","author":"Kalra","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.014_bib0455","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1078-0432.CCR-17-1345","article-title":"Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses","volume":"24","author":"Schunselaar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0460","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/1471-2407-14-709","article-title":"Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions","volume":"14","author":"Szulkin","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0465","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1038\/s41598-018-21200-8","article-title":"In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening","volume":"8","author":"Mazzocchi","year":"2018","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0470","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic t cells in PD-L1-Positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0475","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in immune cell content in malignant pleural mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.semcancer.2019.09.014_bib0480","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98575","article-title":"Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma","volume":"3","author":"Lee","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.semcancer.2019.09.014_bib0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0490","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0495","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"issue":"13","key":"10.1016\/j.semcancer.2019.09.014_bib0500","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0505","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0510","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2019.09.014_bib0515","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(17)30521-1","article-title":"Calling time on the immunotherapy gold rush","volume":"18","author":"O. The Lancet","year":"2017","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0520","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a murine model of malignant mesothelioma","volume":"52","author":"Davis","year":"1992","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/019262339702500605","article-title":"Growth factor responses and protooncogene expression of murine mesothelial cell lines derived from asbestos-induced mesotheliomas","volume":"25","author":"Goodglick","year":"1997","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0530","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12885-017-3382-6","article-title":"Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma","volume":"17","author":"Sneddon","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2019.09.014_bib0535","doi-asserted-by":"crossref","first-page":"22850","DOI":"10.1038\/srep22850","article-title":"Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells","volume":"6","author":"Mezzapelle","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0540","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.semcancer.2019.09.014_bib0545","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1173299","article-title":"Murine mesothelioma induces locally-proliferating IL-10(+)TNF-alpha(+)CD206(-)CX3CR1(+) M3 macrophages that can be selectively depleted by chemotherapy or immunotherapy","volume":"5","author":"Jackaman","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0550","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/2326-6066.CIR-17-0530","article-title":"AMD3100 augments the efficacy of mesothelin-targeted, immune-activating VIC-008 in mesothelioma by modulating intratumoral immunosuppression","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.semcancer.2019.09.014_bib0555","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0560","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"issue":"21","key":"10.1016\/j.semcancer.2019.09.014_bib0565","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-14-0473","article-title":"Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2019.09.014_bib0570","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-014-1597-9","article-title":"Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma","volume":"63","author":"Wu","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0575","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/jcp.26830","article-title":"Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas","volume":"233","author":"Sementino","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"24","key":"10.1016\/j.semcancer.2019.09.014_bib0580","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/onc.2013.280","article-title":"Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma","volume":"33","author":"Guo","year":"2014","journal-title":"Oncogene"},{"issue":"42","key":"10.1016\/j.semcancer.2019.09.014_bib0585","doi-asserted-by":"crossref","first-page":"E6409","DOI":"10.1073\/pnas.1613601113","article-title":"Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma","volume":"113","author":"McFadden","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.semcancer.2019.09.014_bib0590","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.4155\/fmc-2018-0292","article-title":"Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs","volume":"11","author":"Sisler","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.semcancer.2019.09.014_bib0595","first-page":"118","article-title":"Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses","volume":"1","author":"Gurule","year":"2018","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"10.1016\/j.semcancer.2019.09.014_bib0600","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","article-title":"Recurrent tumor cell-intrinsic and -Extrinsic alterations during MAPKi-Induced melanoma regression and early adaptation","volume":"7","author":"Song","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2019.09.014_bib0605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1028","article-title":"Targeted therapies: immunologic effects and potential applications outside of Cancer","volume":"58","author":"Kersh","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"7668","key":"10.1016\/j.semcancer.2019.09.014_bib0610","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.semcancer.2019.09.014_bib0615","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/1078-0432.CCR-18-0871","article-title":"Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics","volume":"25","author":"Miyauchi","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2019.09.014_bib0620","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Usami","year":"2006","journal-title":"Cancer Sci."},{"issue":"47","key":"10.1016\/j.semcancer.2019.09.014_bib0625","doi-asserted-by":"crossref","first-page":"76577","DOI":"10.18632\/oncotarget.10428","article-title":"Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines","volume":"7","author":"Monica","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2019.09.014_bib0630","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-6-130","article-title":"Characterization of human malignant mesothelioma cell lines orthotopically implanted in the pleural cavity of immunodeficient mice for their ability to grow and form metastasis","volume":"6","author":"Martarelli","year":"2006","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2019.09.014_bib0635","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00418-004-0701-1","article-title":"Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis","volume":"122","author":"Philippeaux","year":"2004","journal-title":"Histochem. Cell Biol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X19302883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:40:51Z","timestamp":1778582451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X19302883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":127,"alternative-id":["S1044579X19302883"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.014","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}